The
Bio-Rad Laboratories have been experiencing various challenges, with the
stock recently touching a
52-week low of $262.11 amid market shifts, and reported
slumps in share prices.
Q4 earning and
revenue estimates were
missed, which further affected the stock negatively. However,
several investments were made by entities such as
Blackhawk Capital Partners and
Fjarde AP Fonden Fourth Swedish National Pension Fund. The company's offer to acquire
Stilla might cause an increase in the stock price. Bio-Rad is set to
present at J.P. Morgan's 43rd Annual Healthcare Conference 2025. There is also a
risk associated with bio-rad as
uncertainty and conservatism continue to hold the stock back from its full potential. While it reported the fourth-quarter and full-year 2024's financial results, the company cut the revenue forecast due to weak biotech demand.
Bio-Rad Laboratories Stocks News Analytics from Mon, 09 Nov 2015 08:00:00 GMT to Sat, 01 Mar 2025 12:12:28 GMT -
Rating -6
- Innovation -3
- Information -2
- Rumor -4
